Explore all the latest information in acute lymphoblastic leukemia, arranged by key congresses and meetings. Listed below are recently updated congresses and meetings.
Have you seen an improvement in OS for patients who relapse after HSCT over the past 20 years?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the...
What is new in CAR T-cell therapy for ALL?
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Arnon Nagler, Tel Aviv...
Advances of cell therapies in China: Reducing manufacturing time with FasT dual CAR T-cells
The Multiple Myeloma Hub previously summarised activities on chimeric antigen receptor (CAR) T cells in...
What is new for CAR T-cell therapy for adult patients with ALL?
During the 3rd European CAR T-cell Meeting, the ALL Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, What is new...
Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL
Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two...
Hyper-CVAD with sequential blinatumomab for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative B-cell ALL
Despite high rates of complete remissions, long-term...
When should we consider allo-HSCT in a patient with ALL? And when not?
During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub spoke to Sebastian Giebel,...
Old and new ADCs for the treatment of ALL and AML
Since the beginning of their development in the early 1980s, a lot of progress has been made in the development of monoclonal antibodies (mAbs) for...
American Society of Hematology
EHA–EBMT European CAR T-Cell Meetings
European Hematology Association
European Society for Blood and Marrow Transplantation
International Academy for Clinical Hematology
Society of Hematologic Oncology